PASADENA, Calif.--(BUSINESS WIRE)--Dec 18, 2024--

Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the launch of a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of HC002 in healthy adults. HC002 is an investigational, orally bioavailable small molecule under development by Holoclara that is based on molecules identified in worms.

Copyright Business Wire 2024.